By targeting key regulators of apoptosis, such as the Bcl-2 family proteins and caspases, novel therapeutics can potentiate the apoptotic response in cancer cells, thereby inhibiting tumor growth and metastasis. This evidence concerns the gene BCL2 and cancer.